Free Trial
NASDAQ:ABVC

ABVC BioPharma Q3 2023 Earnings Report

ABVC BioPharma logo
$3.23 +0.33 (+11.38%)
Closing price 09/24/2025 04:00 PM Eastern
Extended Trading
$3.28 +0.06 (+1.70%)
As of 09/24/2025 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ABVC BioPharma EPS Results

Actual EPS
-$0.82
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ABVC BioPharma Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ABVC BioPharma Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Wednesday, November 15, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

ABVC BioPharma's Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

ABVC BioPharma Earnings Headlines

Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
See More ABVC BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ABVC BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ABVC BioPharma and other key companies, straight to your email.

About ABVC BioPharma

ABVC BioPharma (NASDAQ:ABVC) is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens. ABVC BioPharma applies its platform to generate both personalized and off-the-shelf candidates, with preclinical and early-stage clinical studies evaluating safety, immunogenicity and preliminary efficacy.

Headquartered in Research Triangle Park, North Carolina, ABVC BioPharma operates research laboratories in North America and collaborates with academic and industry partners to advance its development programs. The company’s leadership team is composed of executives and scientists with experience in peptide chemistry, immunology and clinical development, guiding its efforts to bring new vaccine-based therapies to market.

View ABVC BioPharma Profile

More Earnings Resources from MarketBeat